High-altitude pulmonary hypertension: Effects of captopril on pulmonary and systemic arterial pressures

Journal of Human Hypertension

Volumn 10, Issue SUPPL. 3, 1996, Pages

  Niazova, Z A ^b   Batyraliev, Talantbek A ^a,b   Aikimbaev, K S ^a   Kudaiberdieva, G Z ^b   Akgul, F ^b   Soodanbekova, Y K ^b   Birand, A ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

^b Kyrghyz Institute of Cardiology   (Kyrgyzstan)

Author keywords

Captopril; High altitude pulmonary hypertension; Pulmonary hypertension; Systemic hypertension

Indexed keywords

CAPTOPRIL;

ADULT; ALTITUDE DISEASE; ARTERIAL PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; HEART CATHETERIZATION; HUMAN; HYPERTENSION; LUNG ARTERY PRESSURE; MALE; PULMONARY HYPERTENSION; STATISTICAL ANALYSIS; SYSTOLIC BLOOD PRESSURE;

ADULT; ALTITUDE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CAPTOPRIL; HUMANS; HYPERTENSION, PULMONARY; MIDDLE AGED; PULMONARY CIRCULATION;

EID: 0029744540     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Fisher J et al. Hemodynamic effects of nifedipine vs hydralazine in primary pulmonary hypertension. Am J Cardiol 1984; 54: 646-650.
2. Luji Herrera E, Bialostozky D, Sabrino A. The role of isoproterenol in pulmonary artery hypertension of unknown etiology. Chest 1981; 79: 292-295.
3. Rich S, Brundage BH. High dose calcium channel blocking therapy for primary pulmonary hypertension: evidence of long term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987; 76: 135-141.
4. Ruskin JD, Hutter AM. Primary pulmonary hypertension treated with oral phentolamine. Ann Intern Med 1979; 90: 772-774.
5. Shepher AMM, Irving NA. Differential hemodynamic and sympatoadrenal effects of sodium nitroprusside and hydralazine in hypertensive subjects. J Cardiovasc Pharmacol 1986; 8: 527-533.
6. Kochar MS, Barboriak JJ, Tyson JA, Kalbfleish JH. Effect of betablockers and converting enzyme inhibitors on serum lipids. J Clin Pharmacol 1984; 24: 422-423.
7. Malini PL, Strocchli E, Ambrosioni E, Magnani B. Long-term antihypertensive, metabolic and cellular effects of enalapril. J Hypertens 1984; 2 (Suppl 2): 101-105.
8. Ohman P, Aurell M, Asplund J. A long-term follow-up of patients with essential hypertension treated with captopril. Acta Med Scand 1984; 216: 53-56.
9. Weinberger MH. Antihypertensive therapy and lipids. Evidence mechanism and implications. Arch Intern Med 1985; 135: 1102-1105.
10. Bertolid LO et al. Effect of captopril on hemodynamics and blood gases in chronic obstructive lung disease with pulmonary hypertension. J Respiration 1986; 49: 251-256.
11. Niarchos AP, Whitman HH, Goldstein GE, Larogh JH. Hemodynamic effects of captopril in pulmonary hypertension of collagen vascular disease. Am Heart J 1982; 104: 834-838.
12. Berkas S, Melman KL. Effect of angiotensin II blockade on hypoxic pulmonary vasoconstriction in vitro and in vivo in the cat (abstract). Clin Res 1974; 22: 231 A.
13. Sada T et al. Cytosolic free calcium of aorta in hypertensive rats. Chronic inhibition of angiotensin converting enzyme. Hypertension 1990; 16: 245-251.
14. Milledge JS, Catley DM. Renin aldosterone and converting enzyme during exercise and acute hypoxia in humans. J Appl Physiol 1982; 52: 320-323.
15. Slater JDH et al. Control of aldosterone secretion during acclimatization to hypoxia in man. Clin Sci 1969; 37: 327-341.